Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Eylea 114.3 mg/ml solution for injection

Active Ingredient:
aflibercept
Company:  
Bayer plc See contact details
ATC code: 
S01LA05
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Audio/Video
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

EYLEA DMO Patient Guide

Your guide to Eylea - for the treatment of visual impairment due to diabetic macular oedema (DMO)

{pdf_link}

Eylea Prescriber Guide

{healthcare_pro_orange} For Healthcare Professionals

Eylea Prescriber Guide (v9.0) for Eylea 40 mg/ml and Eylea 114.3 mg/ml

{pdf_link}

EYLEA WAMD Patient Guide

Your guide to Eylea - for the treatment of neovascular (wet) age-related macular degeneration (AMD).

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Bayer plc
Company image
Address
400 South Oak Way, Reading, Berkshire, RG2 6AD
Medical Information e-mail
[email protected]
WWW
http://www.bayer.co.uk
Telephone
+44 (0)118 206 3000